research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:01:01 ON 01 OCT 2006

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:01:17 ON 01 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10566562.str

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 19	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 20	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific





chain nodes :
10 11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 6-17 7-16 9-10 11-12 11-14 12-13 12-15
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
5-6 5-9 5-11 6-17 7-16 11-14 12-15
exact bonds :
1-2 1-6 2-3 3-4 4-7 6-7 7-8 8-9 9-10 11-12 12-13
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

Stereo Bonds:

10-9 (Single Wedge).

Stereo Chiral Centers:

9 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 9

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:01:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED         2 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:01:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       45 TO ITERATE

100.0% PROCESSED        45 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

L3             0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10566562a.str
```





chain nodes :
10 11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 9-10 11-12 11-14 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
5-6 5-9 5-11 11-14
exact bonds :
1-2 1-6 2-3 3-4 4-7 6-7 7-8 8-9 9-10 11-12 12-13
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS

Stereo Bonds:

10-9 (Single Wedge).

Stereo Chiral Centers:

9 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 9

L4 STRUCTURE UPLOADED

=> d 14
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> d l4
L4 HAS NO ANSWERS
L4                STR
```




```
G1 X

Structure attributes must be viewed using STN Express query preparation.


=> s l4
SAMPLE SEARCH INITIATED 15:43:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       42 TO ITERATE

100.0% PROCESSED       42 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          452 TO     1228
PROJECTED ANSWERS:               0 TO        0

L5             0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 15:43:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      951 TO ITERATE

100.0% PROCESSED      951 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L6             0 SEA SSS FUL L4

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   334.76     334.97

STN INTERNATIONAL LOGOFF AT 15:43:42 ON 01 OCT 2006
```

```
=> s l4
SAMPLE SEARCH INITIATED 15:03:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        7 TO ITERATE

100.0% PROCESSED         7 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            7 TO      298
PROJECTED ANSWERS:               0 TO        0

L5             0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 15:03:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      136 TO ITERATE

100.0% PROCESSED       136 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

L6             0 SEA SSS FUL L4

=>
Uploading C:\Program Files\Stnexp\Queries\10566562b.str
```





```
chain nodes :
10  11  12  13
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
5-11  9-10  11-12  11-13
ring bonds :
1-2  1-6  2-3  3-4  4-7  5-6  5-9  6-7  7-8  8-9
exact/norm bonds :
5-6  5-9  5-11  11-13
exact bonds :
1-2  1-6  2-3  3-4  4-7  6-7  7-8  8-9  9-10  11-12
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS

Stereo Bonds:

10-9 (Single Wedge).
```

Stereo Chiral Centers:

9 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 9

L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l7
SAMPLE SEARCH INITIATED 15:17:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 204 TO ITERATE

100.0% PROCESSED 204 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3224 TO 4936
PROJECTED ANSWERS: 93 TO 587

L8 17 SEA SSS SAM L7

=> s l7 sss fyll
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms. L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles. The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s l7 sss full
FULL SEARCH INITIATED 15:18:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4244 TO ITERATE

100.0% PROCESSED 4244 ITERATIONS 333 ANSWERS

SEARCH TIME: 00.00.01

L9 333 SEA SSS FUL L7

=>
Uploading C:\Program Files\Stnexp\Queries\10566562c.str





chain nodes :
10 11 12 13 14 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 6-16 7-15 9-10 11-12 11-13 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
5-6 5-9 5-11 6-16 7-15 11-13 12-14
exact bonds :
1-2 1-6 2-3 3-4 4-7 6-7 7-8 8-9 9-10 11-12
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

Stereo Bonds:

10-9 (Single Wedge).

Stereo Chiral Centers:

9 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 9

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l10
SAMPLE SEARCH INITIATED 15:19:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      143 TO ITERATE

100.0% PROCESSED      143 ITERATIONS                                  12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          2143 TO     3577
PROJECTED ANSWERS:               33 TO      447

L11          12 SEA SSS SAM L10

=> s l10 sss full
FULL SEARCH INITIATED 15:20:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     3176 TO ITERATE

100.0% PROCESSED     3176 ITERATIONS                                 242 ANSWERS
SEARCH TIME: 00.00.01

L12         242 SEA SSS FUL L10

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     679.64     679.85

FILE 'HCAPLUS' ENTERED AT 15:20:09 ON 01 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 1 Oct 2006 VOL 145 ISS 15
FILE LAST UPDATED: 29 Sep 2006 (20060929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:01:01 ON 01 OCT 2006)

FILE 'REGISTRY' ENTERED AT 15:01:17 ON 01 OCT 2006
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 0 S L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 17 S L7
L9 333 S L7 SSS FULL
L10 STRUCTURE UPLOADED
L11 12 S L10
L12 242 S L10 SSS FULL

FILE 'HCAPLUS' ENTERED AT 15:20:09 ON 01 OCT 2006

=> s l12
L13 1516 L12

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.59	687.44

FILE 'REGISTRY' ENTERED AT 15:22:05 ON 01 OCT 2006

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and

predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10566562d.str





chain nodes :
10 11 12 13 14 15 16 18
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 6-16 7-15 9-10 11-12 11-13 12-14 12-18
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
5-6 5-9 5-11 6-16 7-15 11-13 12-14
exact bonds :
1-2 1-6 2-3 3-4 4-7 6-7 7-8 8-9 9-10 11-12 12-18
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS

Stereo Bonds:

10-9 (Single Wedge).

Stereo Chiral Centers:

9 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 9

L14 STRUCTURE UPLOADED

=> d l14
L14 HAS NO ANSWERS

L14 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l14
SAMPLE SEARCH INITIATED 15:22:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      143 TO ITERATE

100.0% PROCESSED      143 ITERATIONS                          12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2143 TO     3577
PROJECTED ANSWERS:              33 TO      447

L15          12 SEA SSS SAM L14

=> s l14 sss full
FULL SEARCH INITIATED 15:22:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     3176 TO ITERATE

100.0% PROCESSED     3176 ITERATIONS                         240 ANSWERS
SEARCH TIME: 00.00.01

L16         240 SEA SSS FUL L14

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              166.94     854.38

FILE 'HCAPLUS' ENTERED AT 15:22:41 ON 01 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 1 Oct 2006 VOL 145 ISS 15
FILE LAST UPDATED: 29 Sep 2006 (20060929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 15:01:01 ON 01 OCT 2006)

     FILE 'REGISTRY' ENTERED AT 15:01:17 ON 01 OCT 2006
L1             STRUCTURE UPLOADED
L2           0 S L1
L3           0 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5           0 S L4
L6           0 S L4 SSS FULL
L7             STRUCTURE UPLOADED
L8          17 S L7
L9         333 S L7 SSS FULL
L10            STRUCTURE UPLOADED
L11         12 S L10
L12        242 S L10 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 15:20:09 ON 01 OCT 2006
L13       1516 S L12

     FILE 'REGISTRY' ENTERED AT 15:22:05 ON 01 OCT 2006
L14            STRUCTURE UPLOADED
L15         12 S L14
L16        240 S L14 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 15:22:41 ON 01 OCT 2006

=> s l16
L17       1516 L16

=> s l17 and perindopril
          1109 PERINDOPRIL
L18        979 L17 AND PERINDOPRIL

=> s l18 and process
       2315128 PROCESS
       1571514 PROCESSES
       3455450 PROCESS
                 (PROCESS OR PROCESSES)
L19          66 L18 AND PROCESS

=> s l19 and p/dt
       5435395 P/DT
```

```
L20         42 L19 AND P/DT

=> s l20 and us/pc
       1595126 US/PC
L21         19 L20 AND US/PC

=> d l21 ibib abs hitstr tot

L21  ANSWER 1 OF 19  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2006:796623  HCAPLUS
DOCUMENT NUMBER:          145:230528
TITLE:                    Process for making highly pure
                          perindopril erbumine
INVENTOR(S):              Kumar, Ashok; Soudagar, Satish Rajanikant; Mathur,
                          Arpana; Shah, Chirag Hasmukh; Gunjal, Sanjay Tukaram;
                          Metil, Dattatray Shamrao; Kelkar, Rahul Suresh;
                          Thakare, Devendra Digambar; Kumar, Bindu Manoj; Nair,
                          Raji
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 6pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2006178422         A1    20060810    US 2005-140226           20050527 <--
PRIORITY APPLN. INFO.:                       IN 2004-MU566        A   20040531
OTHER SOURCE(S):          CASREACT 145:230528
AB   A process for the synthesis and isolation of
     (2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-
     oxopropyl]octahydro-1H-indole-2-carboxylic acid and its tert-butylamine
     salt, comprises the amidation of (2S,3aS,7aS)-octahydroindole-2-carboxylic
     acid benzyl ester and N-[(S)1-carboxybutyl]-(S)-alanine Et ester in
     nonreactive solvents in turn avoiding the formation of the impurity
     N-acetyl (2S,3aS,7aS)-octahydroindole-2-carboxylic acid benzyl ester.  The
     de-protection of benzyl ester group is optimized by catalytic
     hydrogenolysis and then isolation of the product from an aqueous layer by
     extraction using an organic solvent, which eliminates the need for
lyophilization.
     This yields perindopril erbumine free of contaminants derivable
     from dicyclohexylcarbodiimide (e.g., dicyclohexylurea) and impurities
     originated by the use of Et acetate.
IT   82834-16-0P, Perindopril
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (in a process for making highly pure perindopril
        erbumine)
RN   82834-16-0  HCAPLUS
CN   1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-
     (ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI)
     (CA INDEX NAME)

Absolute stereochemistry.  Rotation (-).
```



IT 107133-36-8P, Perindopril erbumine
RL: SPN (Synthetic preparation); PREP (Preparation)
(process for making highly pure perindopril erbumine)
RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



L21 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:100738 HCAPLUS
DOCUMENT NUMBER: 144:198849

TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2006024365	A1	20060202	US 2005-134633	20050519	<--
IN 193042	A	20040626	IN 2002-MU697	20020805	
US 2004096499	A1	20040520	US 2003-630446	20030729	<--

PRIORITY APPLN. INFO.:

IN 2002-MU697	A	20020805
IN 2002-MU699	A	20020805
IN 2003-MU80	A	20030122
IN 2003-MU82	A	20030122
US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

IT 80828-32-6, Indolapril hydrochloride 82834-16-0, Perindopril 87679-37-6, Trandolapril 95153-31-4
, Perindoprilat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 80828-32-6 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, monohydrochloride, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 87679-37-6 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aR,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 95153-31-4 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-carboxybutyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1201076 HCAPLUS
DOCUMENT NUMBER: 143:446810
TITLE: Processes for the preparation of alpha polymorph of perindopril erbumine
INVENTOR(S): Joshi, Narendra Shriram; Bhirud, Shekhar Bhaskar; Rao, Kodali Eswara
PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Limited, India
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005250706	A1	20051110	US 2005-122731	20050505 <--
WO 2005108365	A1	20051117	WO 2005-IB1233	20050506

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2004-MU531 A 20040507
US 2004-572402P P 20040519
OTHER SOURCE(S): MARPAT 143:446810
AB A process for the preparation of an alpha polymorph of

perindopril erbumine is provided comprising (a) forming a solution comprising perindopril erbumine in one or more ketones; (b) heating the solution to reflux; and (c) cooling the solution to a temperature sufficient to form the alpha polymorph of perindopril erbumine. The alpha polymorphs of perindopril erbumine obtained herein have a high purity level.

IT 107133-36-8P, Perindopril erbumine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(of perindopril erbumine α-polymorph)

RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



L21 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:698368 HCAPLUS
DOCUMENT NUMBER: 143:173145
TITLE: Preparation of perindopril
INVENTOR(S): Bhirud, Shekhar Bhaskar; Ahmed, Suhail; Chandrasekhar, Batchu; Purushotham, Vandanapu Loka Appala
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2005171165	A1	20050804	US 2004-985097		20041110	<--
PRIORITY APPLN. INFO.:			IN 2003-MU1179	A	20031112	
			US 2004-569041P	P	20040507	

OTHER SOURCE(S): CASREACT 143:173145
GI



I



II

AB A process for preparing a novel intermediate, oxathiazolidinedione I, in the preparation of perindopril is provided. Thus, reacting thionyl chloride in CH_2Cl_2 with imidazole and N-1(S)-(carboxyethyl)butyl-(S)-alanine gave I. Also provided are improved processes for the preparation of perindopril erbumine comprising (a) reacting I with a silylated octahydroindole-1H-2-carboxylic acid II to form perindopril; and (b) reacting perindopril with tert-butylamine to form perindopril erbumine.

IT 107133-36-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of perindopril and perindopril erbumine)

RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



IT 82834-16-0P, Perindopril
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of perindopril and perindopril erbumine)
RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:799452 HCAPLUS
DOCUMENT NUMBER: 141:301435
TITLE: Acidic drug complexes for improved bioavailability and delivery
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082628	A2	20040930	WO 2004-US8112	20040317
WO 2004082628	A3	20041119		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004220264	A1	20041104	US 2004-801134	20040316 <--
AU 2004222305	A1	20040930	AU 2004-222305	20040317
CA 2519126	AA	20040930	CA 2004-2519126	20040317
EP 1603549	A2	20051214	EP 2004-757550	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:
US 2003-454631P P 20030317
US 2004-801134 A 20040316
WO 2004-US8112 A 20040317

OTHER SOURCE(S): MARPAT 141:301435

AB Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition The compns. include a mol. complex formed between an acidic pharmaceutical drug and at least one functional substance. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, methotrexate complex with L-lysine was found to have less skin irritation when applying topically to treat psoriasis on the forearm.

IT 82834-16-0D, Perindopril, complexes with amino acid derivs.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. containing acidic active ingredient complexes with amino acids and their derivs. for improved skin care and treatment of skin conditions)

RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:266897 HCAPLUS
DOCUMENT NUMBER: 140:253917
TITLE: Process for the synthesis of perindopril and its pharmaceutically-acceptable salts
INVENTOR(S): Dubuffet, Thierry; Langlois, Pascal
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1403275	A1	20040331	EP 2003-290485	20030228
EP 1403275	B1	20051019		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 307139	E	20051115	AT 2003-290485	20030228
ES 2250846	T3	20060416	ES 2003-3290485	20030228
AU 2004217599	A1	20040916	AU 2004-217599	20040227
WO 2004078107	A2	20040916	WO 2004-FR446	20040227
WO 2004078107	A3	20041021		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1753906	A	20060329	CN 2004-80005405	20040227
JP 2006519177	T2	20060824	JP 2006-500163	20040227
US 2006149081	A1	20060706	US 2005-547131	20050824 <--

PRIORITY APPLN. INFO.:
EP 2003-290485 A 20030228
WO 2004-FR446 A 20040227

OTHER SOURCE(S): MARPAT 140:253917

AB A method for the synthesis of perindopril involves coupling of (2S)-2,3,4,5,6,7-hexahydro-1H-indolecarboxylic acid (I) or an ester with N-[(S)-1-carbethoxybutyl]-L-alanine, followed by catalytic hydrogenation. I benzyl ester tosylate was prepared by reaction of 1-(1-cyclohexen-1-yl)pyrrolidine with (R)-ICH2CH(NBoc)CO2CH2Ph (Boc = tert-butoxycarbonyl),

followed by deprotection and cyclization. Perindopril was converted into its tert-butylamine salt.

IT 82834-16-0P, Perindopril 107133-36-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(synthesis of perindopril and pharmaceutically-acceptable salts)

RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:182242 HCAPLUS
DOCUMENT NUMBER: 140:223260
TITLE: Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
INVENTOR(S): Tuan, Tai-lan; Benya, Paul D.; Warburton, David
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043026	A1	20040304	US 2003-439267	20030513 <--
WO 2004041155	A2	20040521	WO 2003-US15548	20030513
WO 2004041155	A3	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003301809	A1	20040607	AU 2003-301809	20030513
EP 1509236	A2	20050302	EP 2003-808378	20030513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011172	A	20050426	BR 2003-11172	20030513
CN 1668312	A	20050914	CN 2003-816651	20030513
JP 2006507297	T2	20060302	JP 2004-549899	20030513
PRIORITY APPLN. INFO.:			US 2002-380696P P	20020513
			WO 2003-US15548 W	20030513

AB The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an

excessive accumulation of collagen, prevent the formation of an abnormal scar, and/or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compds., tetramic acid based compds., hydroxyquinolinone based compds., Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.

IT 82834-16-0, Perindopril
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions)

RN 82834-16-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:947713 HCAPLUS
DOCUMENT NUMBER: 139:381760
TITLE: Method for synthesis of perindopril and its pharmaceutically acceptable salts
INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-Pierre
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1367061	A1	20031203	EP 2003-291601	20030630
EP 1367061	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 315043	E	20060215	AT 2003-291601	20030630
ES 2256689	T3	20060716	ES 2003-3291601	20030630
AU 2004253721	A1	20050113	AU 2004-253721	20040628
WO 2005003153	A1	20050113	WO 2004-FR1637	20040628

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CN 1802384	A	20060712	CN 2004-80016014		20040628
US 2006178421	A1	20060810	US 2005-562490		20051222 <--
PRIORITY APPLN. INFO.:			EP 2003-291601	A	20030630
			WO 2004-FR1637	W	20040628

OTHER SOURCE(S): CASREACT 139:381760; MARPAT 139:381760

AB A method for the synthesis of perindopril and its pharmaceutically-acceptable salts (e.g., the tert-butylamine) involves cyclocondensation reaction of N-[(S)-1-carbethoxybutyl]-(S)-alanine with sulfinyl chlorides R1SOCl (R1 = imidazolyl, benimidazolyl, or tetrazolyl) to give Et (2S)-2-[(4S)-4-methyl-2,5-dioxo-1,2,3-oxathiazolidin-3-yl]pentanoate, which is amidated with (2S)-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylic acid and hydrogenated over 10% Pt/C to give perindopril.

IT 82834-16-0P, Perindopril 107133-36-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(synthesis of perindopril via cyclocondensation of carbethoxybutylalanine with imidazolesulfinyl chloride)

RN 82834-16-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 107133-36-8 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:912601 HCAPLUS
DOCUMENT NUMBER: 139:386393
TITLE: Stable formulations of angiotensin converting enzyme (ACE) inhibitors
INVENTOR(S): Stofik, Scott; Gwozdz, Robert; Pelloni, Christopher; James, John C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003215526	A1	20031120	US 2003-384246	20030307 <--
PRIORITY APPLN. INFO.:			US 2002-362737P P	20020308

AB Disclosed are a stable pharmaceutical composition comprising (1) a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor which is susceptible to degradation or its salt; (2) a greater than stoichiometric amount of an alkali or alkaline earth metal carbonate, relative to the amount of ACE inhibitor or its salt; and (3) a pharmaceutically acceptable carrier; and a process for the manufacture of such compns. For example, moexipril·HCl was intimately blended with NaHCO3 prior to wet granulation to give granules containing moexipril·HCl 15, NaHCO3 1.2, lactose monohydrate 150.3, crospovidone 6, and pregelatinized starch 16 parts, which were further tableted by adding Crospovidone 4 parts and

Mg stearate 1 part. After storage at 40° and 75 % relative humidity for 4 wks, .apprx.0.4 % degradation products were observed

IT 82834-16-0, Perindopril 87679-37-6, Trandolapril
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable formulations of angiotensin converting enzyme inhibitors)

RN 82834-16-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 87679-37-6 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aR,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:609507 HCAPLUS

DOCUMENT NUMBER: 139:149930

TITLE: Process for the preparation of high purity perindopril and intermediates useful in its synthesis

INVENTOR(S): Simig, Gyula; Mezei, Tibor; Porcs-Makkay, Marta; Mandi, Attila

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1333026	A1	20030806	EP 2002-290206	20020130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2474003	AA	20030807	CA 2003-2474003	20030129
WO 2003064388	A2	20030807	WO 2003-IB691	20030129
WO 2003064388	A3	20040205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EE 200400107	A	20041015	EE 2004-107	20030129
BR 2003007293	A	20041221	BR 2003-7293	20030129
CN 1622936	A	20050601	CN 2003-802714	20030129
US 2005119492	A1	20050602	US 2003-503272	20030129 <--
JP 2005521667	T2	20050721	JP 2003-564011	20030129
NO 2004003472	A	20040820	NO 2004-3472	20040820
BG 108858	A	20050531	BG 2004-108858	20040827
PRIORITY APPLN. INFO.:			EP 2002-290206 A	20020130
			WO 2003-IB691 W	20030129

OTHER SOURCE(S): MARPAT 139:149930

AB The invention relates to 1-[2(S)-[1(S)-(ethoxycarbonyl)butylamino]propionyl]-(3aS,7aS)octahydroindole-2(S)-carboxylic acid (perindopril) and its tert-butylamine salt, free of contaminants derivable from dicyclohexylcarbodiimide, and a process for their synthesis. The invention also relates to N-[1-(ethoxycarbonyl)butyl]-N-(alkoxycarbonyl)alanine intermediates used in the synthesis of perindopril, a known ACE inhibitor. Thus, N-[1-(ethoxycarbonyl)butyl]-N-(ethoxycarbonyl)alanine, prepared by ethoxycarbonylation of N-[1-(ethoxycarbonyl)butyl]alanine, was treated with thionyl chloride in CH2Cl2 and acylated by perhydroindole-2-carboxylic acid in THF at reflux for 4-4.5 h. The product was treated with tert-butylamine to afford 55% perindopril eburmine.

IT 82834-16-0P, Perindopril 107133-36-8P, Perindopril ebumine
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparation of high purity perindopril and intermediates useful in its synthesis)

RN 82834-16-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:77804 HCAPLUS
DOCUMENT NUMBER: 138:107004
TITLE: A process for the preparation of perindopril, its analogs and salts using

2,5-dioxooxazolidine intermediate compounds
INVENTOR(S): Cid, Pau
PATENT ASSIGNEE(S): Adir, Fr.
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1279665	A2	20030129	EP 2002-16262	20020723
EP 1279665	A3	20030312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2003010142	A2	20030206	WO 2002-EP8223	20020723
WO 2003010142	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2002011422	A	20040817	BR 2002-11422	20020723
CN 1529694	A	20040915	CN 2002-814322	20020723
JP 2005501829	T2	20050120	JP 2003-515501	20020723
ZA 2004000323	A	20050117	ZA 2004-323	20040115
US 2004248814	A1	20041209	US 2004-484672	20040712 <--
PRIORITY APPLN. INFO.:			EP 2001-500197 A	20010724
			WO 2002-EP8223 W	20020723

OTHER SOURCE(S): MARPAT 138:107004

AB Perindopril [(2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl]oc tahydro-1H-indole-2-carboxylic acid] or its analogs or salts were prepared by treating RcCH(CO2Ra)NHCHRbCO2H (Ra, Rb = C1-4 alkyl, Rc = C1-6alkyl) with X2C:O (X is a leaving group) to give a 2,5-dioxooxazolidine, which reacts with octahydro-1H-indole-2-carboxylic acid or ester to give the desired product. In an example, N,N'-carbonyldiimidazole was added to a suspension of N-[(S)-1-carbethoxybutyl]-(S)-alanine in CH2Cl2 and the mixture kept at 0° for 1 h. (2S,3aS,7aS)-octahydroindole-2-carboxylic acid was added at -5°C and the solution kept at this temperature for 1 h to give 80% perindopril (isolated as the tert-butylamine salt).

IT 82834-16-0P, Perindopril 107133-36-8P, Perindopril erbumine
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of perindopril using dioxooxazolidine intermediate)

RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



L21 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:754995 HCAPLUS
DOCUMENT NUMBER: 137:268473
TITLE: Porous drug matrices and methods of manufacture thereof
INVENTOR(S): Straub, Julie; Altreuter, David; Bernstein, Howard;

Chickering, Donald E.; Khattak, Sarwat; Randall, Greg
PATENT ASSIGNEE(S): Acusphere Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U. S. 6,395,300.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142050	A1	20021003	US 2002-53929	20020122 <--
US 6395300	B1	20020528	US 1999-433486	19991104 <--
EP 1642572	A1	20060405	EP 2005-27194	20000525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
CN 1823737	A	20060830	CN 2005-10136940	20000525
US 6645528	B1	20031111	US 2000-694407	20001023 <--
US 6932983	B1	20050823	US 2000-706045	20001103 <--
ZA 2001010347	A	20030730	ZA 2001-10347	20011218
US 2005048116	A1	20050303	US 2004-924642	20040824 <--
US 2005058710	A1	20050317	US 2004-928886	20040827 <--

PRIORITY APPLN. INFO.:

US 1999-136323P	P	19990527
US 1999-158659P	P	19991008
US 1999-433486	A2	19991104
US 2000-186310P	P	20000302
CN 2000-808161	A3	20000525
EP 2000-939365	A3	20000525
US 2002-53929	A3	20020122

AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Thus, 5.46 g of PEG 8000, 0.545 g of prednisone, and 0.055 g of Span 40 were dissolved in 182 mL of methylene chloride. A solution of 3.27 g of ammonium bicarbonate in 18.2 mL of water was added to the organic solution (phase ratio 1:10) and homogenized for 5 min at 16,000 RPM.

The resulting emulsion was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas.

IT 82834-16-0, Perindopril 87679-37-6, Trandolapril
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(porous drug matrixes and methods of manufacture thereof)

RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 87679-37-6 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aR,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2002:504616 HCAPLUS
DOCUMENT NUMBER:	137:68194
TITLE:	Thermoformable solid pharmaceutical composition for controlled release of perindopril
INVENTOR(S):	Wuthrich, Patrick; Rolland, Herve; Briault, Gilles; Pichon, Gerard; Tharrault, Francois
PATENT ASSIGNEE(S):	Les Laboratoires Servier, Fr.
SOURCE:	PCT Int. Appl., 22 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	French
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051407	A1	20020704	WO 2001-FR4133	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
FR 2818550	A1	20020628	FR 2000-17013	20001226
FR 2818550	B1	20030207		
CA 2432896	AA	20020704	CA 2001-2432896	20011221
EP 1345605	A1	20030924	EP 2001-989653	20011221
EP 1345605	B1	20050720		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016536	A	20031021	BR 2001-16536	20011221
JP 2004518666	T2	20040624	JP 2002-552552	20011221
NZ 526405	A	20041224	NZ 2001-526405	20011221
AT 299704	E	20050815	AT 2001-989653	20011221
PT 1345605	T	20051130	PT 2001-989653	20011221
ES 2244672	T3	20051216	ES 2001-1989653	20011221
ZA 2003004405	A	20040625	ZA 2003-4405	20030605
NO 2003002738	A	20030616	NO 2003-2738	20030616
US 2004115227	A1	20040617	US 2003-451937	20030626 <--
HK 1063739	A1	20060113	HK 2004-106635	20040903
PRIORITY APPLN. INFO.:			FR 2000-17013 A	20001226
			WO 2001-FR4133 W	20011221

AB The invention concerns a novel solid pharmaceutical composition, with controlled release, obtained by hot-process thermoforming of a mixture based on polymers belonging to the polymethacrylate family, and perindopril or one of its pharmaceutically acceptable salts. Controlled-release pharmaceutical were prepared by extrusion of 2% perindopril tert-butylamine salt and 98% Eudragit E-100 at 95°. Dissoln. rate of the composition was studied.

IT 82834-16-0, Perindopril 107133-36-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermoformable solid pharmaceutical composition for controlled release of perindopril)

RN 82834-16-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:816626 HCAPLUS
DOCUMENT NUMBER: 135:344373
TITLE: Process for preparing the novel γ crystalline form of the diuretic perindopril

tert-butylamine salt

INVENTOR(S): Pfeiffer, Bruno; Ginot, Yves-Michel; Coquerel, Gerard; Beilles, Stephane

PATENT ASSIGNEE(S): Adir et Compagnie, Fr.

SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083439	A2	20011108	WO 2001-FR2169	20010706
WO 2001083439	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2811318	A1	20020111	FR 2000-8791	20000706
FR 2811318	B1	20020823		
CA 2415447	AA	20011108	CA 2001-2415447	20010706
AU 2001076420	A5	20011112	AU 2001-76420	20010706
EP 1296948	A2	20030402	EP 2001-954060	20010706
EP 1296948	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012211	A	20030506	BR 2001-12211	20010706
AT 249435	E	20030915	AT 2001-954060	20010706
JP 2003531890	T2	20031028	JP 2001-580868	20010706
JP 3592296	B2	20041124		
PT 1296948	T	20031231	PT 2001-954060	20010706
ES 2206423	T3	20040516	ES 2001-1954060	20010706
NZ 523311	A	20040625	NZ 2001-523311	20010706
EE 200300003	A	20040816	EE 2003-3	20010706
AP 1452	A	20050930	AP 2002-2709	20010706
W: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW				
US 2003158121	A1	20030821	US 2002-312903	20021231 <--
ZA 2003000025	A	20040210	ZA 2003-25	20030102
NO 2003000051	A	20030106	NO 2003-51	20030106
BG 107534	A	20031231	BG 2003-107534	20030205
HR 2003000078	A1	20030430	HR 2003-78	20030206
HR 20030078	B1	20040630		
US 2004248817	A1	20041209	US 2004-811727	20040329 <--
JP 2005002120	A2	20050106	JP 2004-206157	20040713

PRIORITY APPLN. INFO.:

FR 2000-8791	A	20000706
JP 2001-580868	A3	20010706
WO 2001-FR2169	W	20010706
US 2002-312903	B1	20021231

AB The γ crystalline form of the diuretic perindopril tert-butylamine salt (I) is prepared by refluxing a chloroform-I solution, cooling the solution to 0°, and filtering the I γ crystal modification which is characterized by its X-ray diffraction pattern; a I-containing formulation is presented.

IT 107133-36-8
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(process for preparing the novel γ crystalline form of the diuretic perindopril tert-butylamine salt)
RN 107133-36-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82834-16-0
CMF C19 H32 N2 O5

Absolute stereochemistry. Rotation (-).



CM 2

CRN 75-64-9
CMF C4 H11 N



L21 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:564819 HCAPLUS
DOCUMENT NUMBER: 135:142246
TITLE: ACE inhibitor-vasopressin antagonist combinations
INVENTOR(S): Pressler, Millton Lethan
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001054677	A2	20010802	WO 2000-US32569		20001130
WO 2001054677	A3	20020131			
WO 2001054677	C2	20030612			
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2397244	AA	20010802	CA 2000-2397244		20001130
AU 2001018083	A5	20010807	AU 2001-18083		20001130
EP 1253945	A2	20021106	EP 2000-980880		20001130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2000017074	A	20021203	BR 2000-17074		20001130
JP 2003521496	T2	20030715	JP 2001-555655		20001130
US 2003103983	A1	20030605	US 2002-130168		20020509 <--
US 2005234043	A1	20051020	US 2005-152299		20050614 <--
PRIORITY APPLN. INFO.:			US 2000-178169P	P	20000126
			WO 2000-US32569	W	20001130
			US 2002-130168	A1	20020509

OTHER SOURCE(S): MARPAT 135:142246

AB Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and chronic heart failure in mammals. The clin. efficacy of YM087 and combination of ACE inhibitors and vasopressin antagonists was established in animals and humans. A tablet contained conivaptin 25, qunapril hydrochloride 20, lactose 30, corn starch 20, and magnesium stearate 5%.

IT 82834-16-0, Perindopril 87679-37-6, Trandolapril
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACE inhibitor-vasopressin antagonist combinations)

RN 82834-16-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 87679-37-6 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aR,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:861473 HCAPLUS
DOCUMENT NUMBER: 134:32972
TITLE: Porous drug matrixes containing polymers and sugars and methods of their manufacture
INVENTOR(S): Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg
PATENT ASSIGNEE(S): Acusphere, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072827	A2	20001207	WO 2000-US14578	20000525
WO 2000072827	A3	20010125		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6395300	B1	20020528	US 1999-433486	19991104 <--
CA 2371836	AA	20001207	CA 2000-2371836	20000525
CA 2371836	C	20060131		
EP 1180020	A2	20020220	EP 2000-939365	20000525
EP 1180020	B1	20051214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
BR 2000010984	A	20020430	BR 2000-10984	20000525
JP 2003500438	T2	20030107	JP 2000-620939	20000525
NZ 516083	A	20030829	NZ 2000-516083	20000525
AU 768022	B2	20031127	AU 2000-54459	20000525
AT 312601	E	20051215	AT 2000-939365	20000525
EP 1642572	A1	20060405	EP 2005-27194	20000525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
ES 2250141	T3	20060416	ES 2000-939365	20000525

CN 1823737	A	20060830	CN 2005-10136940		20000525
US 2002041896	A1	20020411	US 2001-798824		20010302 <--
US 6610317	B2	20030826			
NO 2001005753	A	20020128	NO 2001-5753		20011126
ZA 2001010347	A	20030730	ZA 2001-10347		20011218
HK 1048956	A1	20060728	HK 2003-101310		20030220
PRIORITY APPLN. INFO.:			US 1999-136323P	P	19990527
			US 1999-158659P	P	19991008
			US 1999-433486	A	19991104
			US 2000-186310P	P	20000302
			CN 2000-808161	A3	20000525
			EP 2000-939365	A3	20000525
			WO 2000-US14578	W	20000525

AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solns., and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Paclitaxel or docetaxel can be provided in a porous matrix form, which allows the drug to be formulated without solubilizing agents and administered as a bolus. For example, a nifedipine-loaded organic solution was prepared by dissolving 9.09 g of PEG 3350, 2.27 g of nifedipine, and 0.009 g of lecithin in 182 mL of methylene chloride. An aqueous solution was prepared by dissolving 3.27 g of NH4HCO3 and 0.91 g of PEG 3350 in 1.82 mL of water. The aqueous and organic solns. were homogenized and resulting emulsion was spray dried. A suspension of the porous nifedipine drug matrix was prepared in 5% dextrose solution at a concentration of 2.5 mg/mL. A bolus injection of the suspension was tolerated when administrated to dogs.

IT 82834-16-0, Perindopril 87679-37-6, Trandolapril
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

RN 82834-16-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 87679-37-6 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aR,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:421569 HCAPLUS
DOCUMENT NUMBER: 131:68144
TITLE: Angiotensin-converting enzyme inhibitor-matrix metalloproteinase inhibitor combinations for treatment of fibrosis, ventricular dilation, and heart failure
INVENTOR(S): Peterson, Joseph Thomas, Jr.; Pressler, Milton Lethan
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932150	A1	19990701	WO 1998-US23993	19981110
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2305436	AA	19990701	CA 1998-2305436	19981110
AU 9915220	A1	19990712	AU 1999-15220	19981110

AU 751701	B2	20020822			
BR 9814422	A	20001010	BR 1998-14422		19981110
EP 1047450	A1	20001102	EP 1998-959416		19981110
EP 1047450	B1	20021002			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2001526245	T2	20011218	JP 2000-525140		19981110
NZ 503962	A	20020328	NZ 1998-503962		19981110
AT 225187	E	20021015	AT 1998-959416		19981110
ES 2184340	T3	20030401	ES 1998-959416		19981110
ZA 9811794	A	19990629	ZA 1998-11794		19981222
US 6133304	A	20001017	US 2000-485253		20000207 <--
MX 200003736	A	20001020	MX 2000-3736		20000417
NO 2000003256	A	20000622	NO 2000-3256		20000622
PRIORITY APPLN. INFO.:			US 1997-68594P	P	19971223
			WO 1998-US23993	W	19981110

OTHER SOURCE(S): MARPAT 131:68144

AB Combinations of ACE inhibitors and MMP inhibitors are useful to slow and reverse the process of fibrosis, ventricular dilation, and heart failure in mammals.

IT 82834-16-0, Perindopril 87679-37-6, Trandolapril
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACE inhibitor-matrix metalloproteinase inhibitor combinations for treatment of fibrosis, ventricular dilation, and heart failure)

RN 82834-16-0 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 87679-37-6 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2S,3aR,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:456086 HCAPLUS
DOCUMENT NUMBER: 127:145194
TITLE: Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
INVENTOR(S): Chobanian, Aram; Brecher, Peter
PATENT ASSIGNEE(S): Trustees of Boston University, USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5645839	A	19970708	US 1995-482819	19950607 <--
US 6139847	A	20001031	US 1997-801512	19970218 <--

PRIORITY APPLN. INFO.: US 1995-482819 A3 19950607

AB A combination of angiotensin inhibitors and nitric oxide stimulators is used to slow and reverse the process of fibrosis in the body. This combination of medicaments is particularly useful in the treatment of a variety of cardiovascular fibrotic pathologies, such as that associated with left ventricular hypertrophy secondary to hypertension, myocardial infarction, and myocarditis.

IT 82834-16-0, Perindopril
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiotensin inhibitor-nitric oxide stimulator combination for fibrosis treatment)

RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L21 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:858706 HCAPLUS
DOCUMENT NUMBER: 123:266119
TITLE: A pharmaceutical product comprising a salicylate of an esterifiable ACE-inhibitor
INVENTOR(S): Byrne, William; Rynne, Andrew
PATENT ASSIGNEE(S): Cal International Ltd., Ire.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9520571	A1	19950803	WO 1995-IE12	19950127
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, HU, JP, LU, NL, NO, PL, RO, RU, SE, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IE, LU, SE, NE				
CA 2182198	AA	19950803	CA 1995-2182198	19950127
AU 9516709	A1	19950815	AU 1995-16709	19950127
EP 741699	A1	19961113	EP 1995-908364	19950127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
GB 2300635	A1	19961113	GB 1996-16297	19950127
GB 2300635	B2	19980617		
JP 09509150	T2	19970916	JP 1995-519969	19950127
ZA 9500703	A	19950929	ZA 1995-703	19950130
US 5852047	A	19981222	US 1996-682663	19960729 <--
PRIORITY APPLN. INFO.:			IE 1994-80 A	19940128
			WO 1995-IE12 A	19950127

AB Salicylates of esterifiable ACE inhibitors, especially captropril-S-aspirinate, and processes for their preparation are described. A pharmaceutical composition (e.g. capsules or tablets) contains the compds. of the invention and may also contain a diuretic and K+ salts.

IT 82834-16-0, Perindopril 95153-31-4, Perindoprilat
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of compns. containing salicylate of esterifiable ACE-inhibitors)

RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 95153-31-4 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-carboxybutyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 82834-16-0D, Perindopril, aspirin derivs.
95153-31-4D, Perindoprilat, aspirin derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of compns. containing salicylate of esterifiable ACE-inhibitors)
RN 82834-16-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 95153-31-4 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-carboxybutyl]amino]-1-oxopropyl]octahydro-, (2S,3aS,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	142.63	997.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.25	-14.25

FILE 'REGISTRY' ENTERED AT 15:33:15 ON 01 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10566562e.str





chain nodes :
10 11 12 13 14 15 16 18
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-11 6-16 7-15 9-10 11-12 11-13 12-14 12-18
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
5-6 5-9 5-11 6-16 7-15 11-13 12-14
exact bonds :
1-2 1-6 2-3 3-4 4-7 6-7 7-8 8-9 9-10 11-12 12-18
isolated ring systems :
containing 1 :

G1:X

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS

Stereo Bonds:

10-9 (Single Wedge).

Stereo Chiral Centers:

9 (Parity=Don't Care)

Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 9

L22 STRUCTURE UPLOADED

=> d l22
L22 HAS NO ANSWERS
L22 STR



G1 X

Structure attributes must be viewed using STN Express query preparation.

```
=> s l22
SAMPLE SEARCH INITIATED 15:33:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       32 TO ITERATE

100.0% PROCESSED       32 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          301 TO      979
PROJECTED ANSWERS:               0 TO        0

L23            0 SEA SSS SAM L22

=> s l22 sss full
FULL SEARCH INITIATED 15:33:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      586 TO ITERATE

100.0% PROCESSED      586 ITERATIONS                                2 ANSWERS
SEARCH TIME: 00.00.01

L24            2 SEA SSS FUL L22

=> FIL HCAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             166.94    1163.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00     -14.25

FILE 'HCAPLUS' ENTERED AT 15:33:49 ON 01 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 1 Oct 2006 VOL 145 ISS 15
FILE LAST UPDATED: 29 Sep 2006 (20060929/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l24
L25 1 L24

=> d l25 ibib abs hitstr tot

L25 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:67669 HCAPLUS
DOCUMENT NUMBER: 106:67669
TITLE: Indolapril
INVENTOR(S): Linan Castellet, Isidro; Oliver Mir, Monica
PATENT ASSIGNEE(S): Farmhispania S. A., Spain; Bioiberica S. A.
SOURCE: Span., 13 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 537841	A1	19860116	ES 1984-537841	19841121
PRIORITY APPLN. INFO.:			ES 1984-537841	19841121

AB The title compound, useful as an antihypertensive (no data), was prepared An indole-2-carboxylic acid derivative was N-acylated by MeCHBrCOBr and NaHCO3 and the product was treated with (S)-PhCH2CH2CH(NH2)CO2Et and Et3N to give Indolapril.
IT 106534-64-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 106534-64-9 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-(2-bromo-1-oxopropyl)octahydro-, [2S-[1(S*),2α,3aβ,7aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 106534-65-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for alkylation of aminobutyric acid derivative)
RN 106534-65-0 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-(2-bromo-1-oxopropyl)octahydro-, [2S-[1(R*),2α,3aβ,7aβ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.23	1179.18
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-15.00

STN INTERNATIONAL LOGOFF AT 15:36:15 ON 01 OCT 2006